Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Declines By 59.1%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 266,300 shares, a drop of 59.1% from the August 31st total of 651,500 shares. Based on an average daily volume of 7,530,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.6% of the shares of the company are short sold.

CERo Therapeutics Stock Performance

NASDAQ CERO traded up $0.00 during midday trading on Friday, hitting $0.10. The company had a trading volume of 4,153,862 shares, compared to its average volume of 4,374,237. The firm has a fifty day simple moving average of $0.14 and a two-hundred day simple moving average of $0.83. CERo Therapeutics has a fifty-two week low of $0.07 and a fifty-two week high of $12.80.

CERo Therapeutics (NASDAQ:CERO) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.33) earnings per share (EPS) for the quarter.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.